Welcome on the Necker-Enfants Malades Institute website
Friday 29 of September, 2023 at 12:00
Interplay Between Endothelial Cells & Monocytes: A Cellular Dialogue
Marc Bajenoff
Ciml – Centre d’Immunologie de Marseille-Luminy, Aix Marseille University
Invité par Elise Dalmas
INEM - Auditorium 1

Marc Bajenoff performed his doctoral training under the supervision of Dr S. Guerder at the Centre d’Immunologie de Marseille Luminy (CIML). He then joined the laboratory of Prof Glaichenhaus (Valbonne, France) and Prof R. Germain at the Lymphocyte Biology Section, National Institutes of Health for his post-doctoral studies. Here, he developed the first applications of the 2-photon methods for intravital imaging to an extensive analysis of the function of stromal elements within lymphoid tissues.

In 2010, Marc Bajenoff established the “Immunobiology of stromal cells” group at CIML and in 2015, he was awarded an ERC consolidator grant to study the dynamics of lymphoid stromal cells. His general research interests are in understanding the immunobiology of stromal cells and how these versatile cells control the immune system at multiple levels. More recently, his laboratory has developed a strong interest in studying the crosstalk between stromal cells and macrophages across tissues.

Friday 6 of October, 2023 at 12:00
From regulatory plasma cells to the resolution of autoimmune disease
Simon Fillatreau
Institut Necker Enfants Malades, Université Paris Cité, APHP Hôpital Necker
Invité par Peter van Endert
INEM - Auditorium 1

Simon Fillatreau studied at Ecole Normale Supérieure. He performed his doctoral training under the supervision of Prof. D. Gray at Imperial College London and then at the University of Edinburg. He was then immediately appointed as group leader at the Deutsches Rheuma-ForschungsZentrum, a Leibniz Institute Berlin where he created the “Immune regulation” team. In 2015, he moved back to Paris as Professor of Immunology at the Université Paris Cité & Institut Necker Enfants Malades where he established the “Immunity in Health and Disease” team. He was awarded an ERC Consolidator Grant to study the regulatory function of antibody-secreting cells in 2014, and an AXA Long-term chair in Translational Immunology in 2015. In 2022, he obtained as coordinator a collaborative Horizon Europe grant to develop autoantigen-specific regulatory T cells for the treatment of type 1 diabetes (ARTiDe). His main research interests lie in the understanding of the regulatory functions of B cells, which he discovered, and T cells in immune-mediated diseases with the perspective of translating discoveries into new therapeutics.
More recently, his laboratory has developed a strong interest in the investigation of the regulatory functions of plasma cells, which led to the discovery of novel plasma cell populations and new insights into the mechanisms involved in the resolution of autoimmune diseases.

Friday 13 of October, 2023 at 12:00
NAD+, autophagy, and AI in brain health and longevity
Evandro Fei Fang
University of Oslo and Akershus University Hospital, Norway
Invité par Lida Katsimpardi
INEM - Auditorium 1

Evandro F. Fang is an Associate Professor of Molecular Gerontology at the University of Oslo and the Akershus University Hospital, Norway. With his group, they are working on the molecular mechanisms of human ageing and age-predisposed neurodegeneration.

After finishing his PhD at the Chinese Universtiy of Hong Kong, he had a 6-year postdoc training with Prof. Vilhelm Bohr on molecular gerontology and Prof. Mark Mattson on neuronal resilience in Alzheimer’s disease at the National Institute on Ageing, Baltimore. He opened his lab in Oslo in the fall of 2017.

The Fang laboratory focuses on the molecular mechanisms behind how cells clear their damaged and aged mitochondria, a process termed “mitophagy”, as well as the roles of the NAD+-mitophagy/autophagy axis in healthy ageing and AD inhibition. NAD+ is a fundamental molecule in life and health and decreases in ageing and AD. Dr Fang is involved in 5 NAD+ based clinical trials, with the overarching goal of establishing novel and safe biological approaches to promote longer and healthier human lives.

He is the founding (co)coordinator of the Norwegian Centre on Healthy Ageing network (NO-Age), the Norwegian National anti-Alzheimer’s disease Network (NO-AD), and the Hong Kong-Nordic Research Network.

Friday 20 of October, 2023 at 12:00
Counter nutri-stress, cold resistance and promoting healthy aging: two targets for three effects and more
Marc Prentki
University of Montreal, Montreal Diabetes Research Center
Invité par Mario Pende
INEM - Auditorium 4

Marc Prentki, PhD, was trained in biochemistry at the university of Geneva. He is currently professor of nutrition at the Université de Montréal and held a Canada Research Chair in Diabetes and Metabolism. Marc was an assistant professor working on diabetes and beta-cell function at the University of Pennsylvania and at the University of Geneva. He currently heads the Montreal Diabetes Research Center. His current research interest are related to the ß-cell in health and diabetes, nutrient excess detoxification processes in various tissues, metabolism and cancer and healthy aging using rodent models and C. elegans. Marc has received several awards including the young researcher award from the federation of European Endocrine Societies and the Albert Renold award from the European Association for the Study of Diabetes.

Friday 27 of October, 2023 at 12:00
Study of leukocyte migration at the single cell level: from cellular mechanisms to immunotherapies.
Pablo Vargas
Institut Necker Enfants Malades
Invité par Peter van Endert
INEM - Amphi 1

Pablo Vargas is the director of the Leukomotion Lab, at the Institut Necker Enfants Malades in Paris, France. The team was created in January 2022, and aims at identifying cellular mechanisms that facilitate immune cell migration in tissues. This work is performed at the single cell level by taking advantage of customized microdevices, which allow the control of the microenvironment in which cells move.

In this seminar, Pablo Vargas will talk about specific mechanisms that leukocytes use to migrate in tissues. He will also discuss on how cell migration can contribute to the physiopathology of immune disorders. Finally, He will show that leukocyte motility can be a powerful tool to identify new specific immunomodulators.

Friday 3rd of November, 2023 at 12:00
Memory B Cell Development, Heterogeneity and Functions: an epigenetic perspective
Mark Shlomchik
Department of Immunology, University of Pittsburgh
Invité par Simon Fillatreau - Matthieu Mahévas
INEM - Auditorium 1

Mark Shlomchik received his medical and doctoral degrees in 1989 from the University of Pennsylvania, where he also completed residency training in pathology and laboratory medicine. In 2004, he joined the faculty at Yale University, rising to the rank of full professor. In July 2013, he was named Chair of Department of Immunology, University of Pittsburgh School of Medicine where he holds the UPMC Endowed Chair for Immunology.

Mark Shlomchik’s lab is interested in systemic autoimmune diseases, long-lived B cell immunity, and immunopathogenesis. He has elucidated the key roles of B cells, Toll-like receptors, and dendritic cells in these diseases; a current focus is understanding the role of T cells, and inherent tissue resistance to them, in systemic autoimmunity. Mark Shlomchik also studies long-lived B cell immunity and has made leading discoveries to elucidate the function of memory B cells and the “germinal center”, where both memory B cells and long-lived antibody forming cells are generated.

In 2017 he co-founded a biotech company, BlueSphere Bio, which aims to deliver personalized T cell immunotherapy for leukemia and solid tumors, based on the patented TCXpress TCR cloning and functionality testing platform he invented.

Friday 17 of November, 2023 at 12:00
Oncoprotein duality: lessons learned from RAS GTPases
Pau Castel
Department of Biochemistry and Molecular Pharmacology at the NYU School of Medicine
Invité par Guillaume Canaud
INEM - Auditorium 1

Dr. Pau Castel is an Assistant Professor at the Department of Biochemistry and Molecular Pharmacology at the New York University School of Medicine. Dr. Castel performed his graduate work at Memorial Sloan Kettering Cancer Center under the supervision of Dr. José Baselga and undertook postdoctoral studies at the University of California San Francisco in the laboratory of Dr. Frank McCormick. His research is aimed at understanding the molecular mechanisms underlying oncoprotein transformation in cancer and congenital disorders, including RASopathies.

The Castel laboratory employs biochemical, signal transduction, and mouse genetics to study oncoproteins of the Ras-MAPK and PI3K pathways with the goal of developing rational-based therapies for these disorders.

Friday 2nd of February, 2024 at 12:00
Mitochondrial mechanotransduction coordinates the nuclear response to forces
Sirio Dupont
University of Padua
Invité par Fabiola Terzi
INEM - Auditorium 1

Sirio Dupont is a unique individual in a family of artists and humanists. He made the unconventional choice to pursue a career in science, earning a Molecular Biology Master's Degree at the University of Padua. His passion for developmental biology led him to pursue a Ph.D., which he successfully completed in 2004, also at the University of Padua.

With outstanding results and an unyielding passion for his field, Professor Dupont entered the world of academia and became an Assistant Professor in 2006, still at the University of Padua. Throughout this journey, his family continued to grow, and he explored new research avenues. Notably, he achieved a 'once in a lifetime' discovery.

In 2013, Professor Dupont took the next step in his career by establishing an independent research group, once again, in Padua. Over the past decade, he has led this research group with enthusiasm, finding immense joy in scientific exploration. Alongside these professional accomplishments, his family continued to thrive, all with the constant presence of his supportive wife.

In recognition of his exceptional contributions to science and his unwavering dedication, Professor Dupont was appointed as a Full Professor in 2023, at the University of Padua.

Friday 9 of February, 2024 at 12:00
New strategies for the diagnostic and treatment of allergic diseases
Laurent Reber
Institut Toulousain des Maladies Infectieuses et Inflammatoires 
Invité par Simon Fillatreau
INEM - Auditorium 1

Laurent Reber completed a Ph.D. at the University of Strasbourg in 2009, conducting research in the laboratory of Nelly Frossard. Following the completion of the Ph.D., they embarked on a postdoctoral fellowship in the laboratory of Steve Galli at Stanford University, where they focused on the biology of mast cells and their pivotal role in allergic diseases.

In 2016, Dr Reber was recruited by INSERM and joined the team led by Pierre Bruhns at Institut Pasteur in Paris. There, they continued their research endeavors, delving deeper into the mechanisms underlying allergic diseases and anaphylaxis.

In 2019, Dr Reber established the ATIP-Avenir team "Asthma, Allergy & Immunotherapy" at the INFINITy Institute in Toulouse, solidifying their commitment to advancing our understanding of these conditions. Notably, in 2022, they achieved the prestigious honor of receiving an ERC Consolidator Grant for their pioneering work in developing long-term therapeutic strategies to address IgE-mediated allergic diseases.

Friday 16 of February, 2024 at 12:00
Unexpected roles of phosphoinositdes in aging and cancer
Emilio Hirsch
University of Torino
Invité par Ganna Panasyuk
INEM - Auditorium 1

Emilio Hirsch is Professor of Experimental Biology at the Medical School of the University of Torino, Italy since 2005. He authored 301 publications, has an h-index of 90 (google Scholar), is EMBO member, FISHR, Scientific Director of the Molinette Research Foundation and Director of the Molecular Biotechnology Center.

Professor Hirsch is co-founder of Kither Biotech, a preclinical stage biopharmaceutical company developing novel therapies for rare pulmonary diseases with high unmet medical needs like Cystic Fibrosis and Idiopathic Pulmonary Fibrosis. He provided seminal contributions in the characterization of phosphoinositide 3-kinases (PI3K) as drug targets in cancer and inflammation.

Lately, he focused his studies on the role of class 2 PI3K and found that the gene PIK3C2A is essential for cytokinesis. Children with loss of function mutations show cell refusion leading to cellular senescence and premature aging (Gulluni et al., Science 2021).


Notice: Undefined variable: contact_addr in /homepages/40/d483507699/htdocs/location.php on line 21
HRH Princess Caroline of Hanover, who through the Princess Grace Foundation, already supports medical research and anything that helps to relieve the sick children in France and around the world, has agreed to commit to our side so that our Center of Molecular medicine continues to meet the current challenges and fight diseases, and in particular the ones affecting children.

INEM - Organigramme